SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC)

MLA

Michelino De Laurentiis, et al. “SOPHIA Analysis by Chemotherapy (Ctx) Choice: A Phase III (P3) Study of Margetuximab (M) + Ctx versus Trastuzumab (T) + Ctx in Patients (Pts) with Pretreated HER2+ Metastatic (Met) Breast Cancer (MBC).” Journal of Clinical Oncology, vol. 38, May 2020, p. 1040. EBSCOhost, https://doi.org/10.1200/jco.2020.38.15_suppl.1040.

APA

Michelino De Laurentiis, Christelle Levy, William J. Gradishar, Shakeela W Bahadur, Gail S. Wright, Javier Cortes, Giuseppe Curigliano, Katarína Petráková, Sutton Edlich, Seock-Ah Im, Edwin P. Rock, Santiago Escrivá, Sam Hong, Jean-Marc Ferrero, David A. Riseberg, Hope S. Rugo, Fatima Cardoso, Mark D. Pegram, Denise A. Yardley, & Sung-Bae Kim. (2020). SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC). Journal of Clinical Oncology, 38, 1040. https://doi.org/10.1200/jco.2020.38.15_suppl.1040

Chicago

Michelino De Laurentiis, Christelle Levy, William J. Gradishar, Shakeela W Bahadur, Gail S. Wright, Javier Cortes, Giuseppe Curigliano, et al. 2020. “SOPHIA Analysis by Chemotherapy (Ctx) Choice: A Phase III (P3) Study of Margetuximab (M) + Ctx versus Trastuzumab (T) + Ctx in Patients (Pts) with Pretreated HER2+ Metastatic (Met) Breast Cancer (MBC).” Journal of Clinical Oncology 38 (May): 1040. doi:10.1200/jco.2020.38.15_suppl.1040.